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Abstract
Purpose We evaluated individualized multimodal oncologi-
cal strategies in patients with bilobular colorectal liver
metastases(biCRC-LM)aswellastheireffectonR0resection
rates, disease-free survival (DFS), and overall survival (OS).
Methods Between January 2001 and December 2008, 64
patients were assigned to straightforward or two-stage liver
resection ± preoperative 5-fluorouracil (5FU)-based chemo-
therapy (CTx). Postoperative strategy after R0-resection was
either “wait and see” or “adjuvant” therapy (3 cycles of CTx
or anti-carcinoembryonic antigen (CEA)-radioimmunother-
apy with
131I-labetuzumab in a dose of 40–50 mCi/m
2).
Results Forty-three initially unresectable patients received
preoperative CTx for downsizing of their biCRC-LM.
Straightforward or two-stage liver resection was intended in
40 and 24 patients, respectively. Histopathologically con-
firmed R0-liver resection could be achieved in 47 patients.
Surgical morbidity and mortality rates were 33% and 1.5%,
respectively. Postoperatively, 26 patients received anti-cancer
therapy (5 × CTx, 21 × anti-CEA-radioimmunotherapy).
After R0-liver resection, median OS was significantly better
compared to R1/R2 resections followed by palliative 5FU-
CTx (38 versus 19 months, p=0.035). There was no
significant difference in DFS (p=0.650) and OS (p=0.435)
between straightforward and two-stage liver resection.
Compared to “wait and see” strategy, the application of
postoperative therapy in adjuvant intent was associated with
ab e t t e rO S( p=0.048).
Conclusion Extensive liver resection within multimodal
treatment concepts is justified in patients with biCRC-LM
when complete resection of all metastases seems to be
achievable.
Keywords Multimodal treatment.Two-stage
hepatectomy.Portal vein ligation.Oncological strategy.
Adjuvant therapy
Introduction
OnlyhistopathologicallyconfirmedR0liverresection(LR)of
colorectal liver metastases (CRC-LM) offers a long-term
survival, and 5-year-survival rates up to 58% have been
reported from specialized centers [1, 2]. Patients with bilobar
colorectal liver metastases (biCRC-LM) represent a particu-
lar challenge as their prognosis is extremely poor. If
complete (R0) LR can be achieved in cases of primary
resectability, even these patients benefit from an extended
surgical intervention and experience a 5-year-survival rate up
to 20% [3]. Unfortunately, up to 70% of patients with
biCRC-LM are primarily unresectable even when assessed
by an experienced hepatobiliary surgeon. These patients
represent an advanced stage of disease with a 5-year-survival
rate below 5% under palliative polychemotherapy [4, 5]. In
the last decade, individualized multimodal approaches using
preoperative chemotherapy and/or two-stage procedures
K. Homayounfar and T. Liersch contributed equally to this manuscript
and study.
K. Homayounfar (*):T. Liersch: M. Niessner:T. Lorf:
H. Becker:B. M. Ghadimi
Department of General and Visceral Surgery,
University Medical Centre, Georg-August University Goettingen,
Robert-Koch-Strasse 40,
37073 Goettingen, Germany
e-mail: khomayounfar@chirurgie-goettingen.de
J. Meller
Department of Nuclear Medicine, University Medical Centre,
Georg-August University Goettingen,
Robert-Koch-Strasse 40,
37073 Goettingen, Germany
Langenbecks Arch Surg (2010) 395:633–641
DOI 10.1007/s00423-010-0604-7including portal vein occlusion (PVO) have been established
aiming to enhance the proportion of initially unresectable
patients with biCRC-LM suitable for secondary R0-LR.
The potential of preoperative chemotherapy has recently
been demonstrated by the randomized multicenter CELIM-
study [6], which confirmed a 28% secondary R0-resection
rate following preoperative 5-fluorouracil (5FU)-based che-
motherapy extended by cetuximab and either oxaliplatin or
irinotecan. Furthermore, the advanced surgical approach of
two-stage hepatectomy with PVO also demonstrated encour-
aging secondary resection rates of 58–75% [7, 8]. However,
as unresectability might be caused not only by bilobar
metastatic spread but also by unilobar disease with small left
lateral liver segments or close relation of CRC-LM to major
intrahepatic structures, the rather technical stratification of
primary unresectability neglects the different oncological
stage of unilobar and bilobar CRC-LM. Recently, Nikfarjam
and colleagues reported a series of 64 patients with CRC-
LM treated within a multimodal treatment concept and
confirmed bilobar spread (n=40) to be an independent
prognostic factor associated with poorer disease-specific
survival (p=0.02) [9]. Besides these results, studies on
multimodal treatment strategies and their oncological out-
come in patients with biCRC-LM are still lacking.
Therefore, the aim of the present study was to analyze our
single-center experience with multimodal strategies including
innovative-targeted therapies like anti-carcinoembryonic an-
tigen (CEA)-radioimmunotherapy [10, 11] on resection rates
and survival in patients with biCRC-LM.
Patients and methods
Study population
Out of 168 consecutive patients surgically treated for
CRC-LM between January 2001 and December 2008,
64 presented with bilobar hepatic involvement diagnosed
by pretherapeutical staging. These patients reflect the
study population of the present investigation. Oncologi-
cal treatment, perioperative data, and survival were retro-
spectively analyzed based on a prospectively designed
database.
The treatment rationale for patients with biCRC-LM was
first to evaluate whether all liver metastases were resectable
by straightforward resection. If that was not possible, we
assessed the possibility of complete resection by a two-
stage procedure with portal vein ligation. Those patients
that seemed to be unresectable even with a two-stage
concept were treated by preoperative systemic 5FU-based
chemotherapy and were re-evaluated for secondary resect-
ability (straightforward or two-stage resection) every three
courses.
Clinicopathologic data concerning surgery and adjuvant
therapy of the primary tumor are summarized in Table 1.O f
the patients, 47 (74%) had locally advanced and distant
metastatic disease stages (8 × UICC III, 39 × UICC IV) at
the time of primary tumor resection. CRC-LM were
classified as synchronous when they had been diagnosed
prior to, during, or up to 3 months after surgery for the
primary tumor. The mean disease-free survival (DFS)
between primary tumor resection and diagnosis of first
CRC-LM was 7± 2.9 (range 0–69) months for all patients.
One patient presented with intrahepatic recurrence.
Staging procedures before liver resection
Pretherapeutical staging included clinical examination, chest
X-ray, abdominal computed tomography (CT) or magnetic
resonance imaging, and serum level of CEA. As we observed
extrahepatic metastases early after LR which presumably
were existent but undetected at the time of LR, staging
procedures were extended to a thoracoabdominal computed
tomography as well as a
18F-fluorodeoxyglucose–positron
emission tomography in January 2006. All staging data were
reviewed by a board of experienced surgical and medical
oncologists and hepatobiliary surgeons.
Table 1 Clinicopathologic data of primary tumor therapy
Parameter Patients
No. %
Sex
Female 18 28
Male 46 72
Primary cancer
Colon 39 61
Rectum
a 25 39
Primary tumor stage at surgery
UICC I 4 6
UICC II 13 20
UICC III 8 13
UICC IV 39 61
Adjuvant 5FU-based chemotherapy
Yes 15 23
No 49 77
Detection of hepatic metastases
Synchronous
b 42 66
Metachronous 22 34
UICC Union Internationale Contre le Cancer
aUp to 16 cm above anocutaneous verge as measured by rigid rectoscopy
according to UICC/TNM 2003
b≤3 months between primary tumor resection and diagnosis of liver
metastases
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Preoperative systemic 5FU-based chemotherapy was applied
for both downsizing of primary unresectable CRC-LM and
assessment of tumor responsiveness. Response to preopera-
tive chemotherapy was measured by an experienced radiolo-
gist using the Response Evaluation Criteria in Solid Tumors
(RECIST) [12]. In accordance with these criteria, partial
remission had been defined as at least 30% decrease and
progressive disease as at least 20% increase in the sum of the
longest diameter of target lesions. Stable disease was present
in any change of size between these two values.
LR was performed according to established surgical
standard operating procedures. In those patients needing LR
of more than four segments due to the distribution of their
CRC-LM, the future remnant liver volume was calculated
preoperatively according to Truant et al. [13] based on CT
scan volumetric estimation. In cases with a future remnant
liver weight to body weight ratio less than 0.5% two-stage
hepatectomy with portal vein ligation (PVL) as previously
described [7] was indicated to preserve sufficient liver
function. During the phase of liver hypertrophy, no
chemotherapy was administered. The use of radiofrequency
ablation (RFA) was limited to two different settings: first,
when resection of a single or multiple metastases was
technically impossible. In these cases, operation was
classified as incomplete (R1) regardless of simultaneous
complete (R0) resection of other CRC-LM. Second, when
LR was canceled due to intrahepatic tumor progression, but
RFA was assumed to be beneficial for local tumor control.
Those patients that experienced surgical exploration ± PVL
without subsequent LR were classified as incomplete (R2)
resection. Postoperative liver insufficiency was defined by
prothrombin time <50% and serum bilirubin >50 μmol/l on
post-op day 5 as described by Balzan et al. [14].
During the study term, the Association of Scientific
Medical Societies in Germany interdisciplinary guidelines
for the treatment of CRC-LM [15] recommended a “wait and
see”strategyafterR0-LR,whichhadbeenthestandardforour
study population. However, over the same period of time, we
performed a phase II trial investigating the feasibility and
safety of single or repeated anti-CEA-radioimmunotherapy
with
131I-labetuzumab (hMN-14 humanized anti-CEA im-
munoglobulin G1—subclass monoclonal antibody, Immuno-
medics Inc. Morris Planes NJ, USA) after R0-resection of
CRC-LM on DFS and overall survival (OS) [10, 11].
Therefore, eligible patients with immunohistochemically
proven CEA-overexpression on CRC-LM cells were enrolled
even after preoperative 5FU-based chemotherapy while the
study was open for recruitment. Alternatively, patients
requesting adjuvant therapy were treated by systemic 5FU-
based chemotherapy according to the investigators’ discre-
tion (FOLFOX or FOLFIRI regimen).
Statistics
Median follow-up was 23 (range 1–83) months. Statistical
comparisons between distinct groups were performed by
Fisher´s exact test. The baseline for survival analyses was
the time point of liver resection with removal of the CRC-
LM. In patients subjected to two-stage procedures, the time
point of second procedure was taken. The Kaplan–Meier
survival estimates method was used to calculate DFS as
well as OS, and significant differences were examined
using the log-rank-test. A difference was considered to be
significant when the p value was less than 0.05. The
analysis was performed using the statistical software
Statistica (StatSoft, Tulsa, OK, USA). Subgroups of
patients were specified as oncologically comparable when
there was no statistical significant difference in all of the
following parameters: primary tumor location (colon versus
rectum), T-stage and N-stage of the primary tumor, UICC-
stage, percentage of patients receiving preoperative chemo-
therapy before LR, distribution of clinical risk scores (Fong
and Nordlinger), and percentage of patients receiving
postoperative anti-cancer therapy in adjuvant intent.
Ethical considerations
All human interventions were performed in accordance
with the ethical standards laid down in the Declaration of
Helsinki as revised in 1983 and have been approved by the
regional ethical committee. All patients gave their written
informed consent.
Results
Figure 1 summarizes the stratification of the study popula-
tion into the different treatment arms. The mean age of our
study population was 60.7±9.4 years. The mean number of
CRC-LM identified by initial staging procedures were 3±1.8
(range 1–7; median 2) with a mean diameter of 3.3±2.2cm
(range 1–12; median 3cm).
Preoperative chemotherapy
Detailed data on the applied drug combinations are
displayed in Table 2. The heterogeneity of regimens has
to be attributed to the diversity of referring medical
oncologists. The 43 patients received a mean number of
5.6±4.4 (median 4; range 2–25) cycles of 5FU-based
chemotherapy regimen which in 95% (41 patients) had
been intensified by the addition of oxaliplatin or irinotecan
and in 42% also by one of the monoclonal antibodies
cetuximab or bevacizumab. In particular, 5FU/folinic acid +
oxaliplatin (FOLFOX) had been chosen in 40% of patients
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used only in 7%. Based on RECIST criteria, preoperative
chemotherapy resulted in partial remission in 16 and stable
disease in 20 patients. Seven patients had minor progressive
disease limited to the liver. However, all patients were
deemed technically resectable at restaging prior to exten-
sive surgery in our department.
Surgical procedures
Operative procedures are summarized in Table 3.T h e
decision on two-stage hepatectomy was made prior to the
first procedure in all 24 patients affected. The corresponding
perioperative complications are displayed in detail in Table 4.
The surgical morbidity and mortality rates were 33% and
1.5%, respectively.
In 51 patients, macroscopically complete resection of all
detectable CRC-LM was achieved. Of these, six patients
were treated only by unilobar LR (1 × minor LR of 1
segment, 5 × right hemihepatectomy of segment V–VIII)
based on downsizing of CRC-LM by preoperative chemo-
therapy. The histopathological examination of the surgical
specimens revealed vital tumor cells at the resection margin
(R1-resection) in four patients (8%). R0-Resection rates in
otherwise oncologically comparable patients treated by
straightforward resection versus two-stage hepatectomy
were not significantly different (p=0.1511).
The surgical approach was non-curative because of unre-
sectable disease in the remaining 13 patients (20%). Eight of
these 13 patients were treated within a two-stage concept using
PVL, but resection of all CRC-LM could not be performed as
they experienced unresectable tumor progression (n=7) or
denied second-stage procedure (n=1). Additionally, four
patients were surgically explored, but LR was also cancelled
due to intraoperatively diagnosed unresectable disease. In one
patient, multiple non-anatomical resections had to be com-
bined with RFA as several metastases were unresectable.
Fig. 1 Therapy algorithm of study population with bilobar CRC-LM (n=64). Study population. Patients with incomplete (R1/R2) resection
received palliative chemotherapy postoperatively. Abbreviations: CRC-LM colorectal liver metastases, LR liver resection, PVL portal vein ligation
Table 2 Preoperative chemotherapy regimens for downsizing of
initially unresectable bilobar colorectal liver metastases (n=43)
Chemotherapy regimen Patients
No. %
5FU/folinic acid alone 2 5
Additional oxaliplatin 17 40
Additional oxaliplatin + cetuximab 4 9
Additional oxaliplatin + bevacizumab 1 2
Additional irinotecan 3 7
Additional irinotecan + cetuximab 3 7
Additional irinotecan + bevacizumab 6 14
Additional oxaliplatin + sequential irinotecan
a 37
Additional oxaliplatin + sequential irinotecan
a + cetuximab 2 5
Additional oxaliplatin + sequential irinotecan
a +
bevacizumab
25
5FU 5-fluorouracil
aEither oxaliplatin followed by irinotecan or vice versa
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Of the 47 patients that had histopathologically confirmed R0
resection of biCRC-LM, 21 patients did not receive postop-
erative anti-cancer therapy in adjuvant intent but had routine
follow-up every 3 months according to national guidelines
[15]. Twenty-six patients received either 3 cycles of 5FU-
based systemic chemotherapy (n=5; 2 × 5FU/folinic acid,
2 × 5FU/folinic acid + oxaliplatin, 1 × 5FU/folinic acid +
irinotecan) or anti-CEA-radioimmunotherapy with
131I-labe-
tuzumab (n=21; 10 × single dose, 11 × repeated dose) in a
dose of 40–50 mCi/m
2.
Follow-up
Median DFS for R0-resected patients (n=47) was 8 months.
There was no statistically significant difference in DFS (p=
0.650) and OS (p=0.435) between the oncologically
comparable patients treated within two-stage concepts with
PVL compared to those having straightforward LR.
Thirty out of 47 patients (64%) developed metastatic
recurrence after potentially curative R0-LR. Being
afflicted in 21 of these 30 patients (70%), the liver was
the main site of metastatic recurrence. In particular,
metastases were confined to the liver in 16 and involved
simultaneous liver and lung in five patients, respectively.
Potentially curative re-resection of all metastases could
be achieved in nine of the 30 patients (30%). In these
nine patients, the metastatic recurrence was limited to
either the liver or the lung.
The median OS of the 47 R0-resected patients was
38 months. This was significantly higher (p=0.035) than of
patients with incomplete (R1/R2) resection followed by
palliative systemic 5FU-based chemotherapy (19 months,
Fig. 2). Stratifying the patients following R0-LR in those
with versus those without postoperative anti-cancer therapy
in adjuvant intent resulted in two otherwise oncologically
comparable subgroups. Receiving anti-cancer therapy post-
operatively was not associated with a significant advantage
in DFS (p=0.269) but in OS (p=0.048) compared to the
“wait and see” strategy (Fig. 3) in those patients who denied
postoperative anti-cancer treatment on behalf of the national
guidelines.
Discussion
There is a consensus between medical oncologists and
hepatobiliary surgeons that resectability of all CRC-LM is
the key issue in curative intended treatment concepts [1,
16]. However, the individual assessment of resectability
might differ even between experienced hepatobiliary
surgeons. This has been demonstrated by the recently
Table 3 Surgical procedures
Procedure Patients
No. %
Surgical exploration only
a 71 1
Minor resection
b 35
Multiple minor resections
c 13 20
Bisegmentectomy segment II/III
d 35
Bisegmentectomy segment II/III + non-anatomical
resection right hemiliver
35
Central liver resection 5 8
Left hemihepatectomy + non-anatomical resection
right hemiliver
12
Right hemihepatectomy 5 8
Right hemihepatectomy + minor resection left hemiliver 5 8
Extended right hemihepatectomy
e 71 1
Right trisegmentectomy 12 19
Of the seven patients with surgical exploration only, four had intra-
operatively diagnosedunresectable disease,and three were treated within
a two-stage concept but experienced unresectable tumor progression
during the interval between the PVL and the scheduled second
exploration. Six patients were treated only by unilobar liver resection
(1×minorresection,5×righthemihepatectomy)basedondownsizingof
CRC-LM by preoperative chemotherapy. The remaining unilobar
resections were performed during first stage procedure within the two-
stage hepatectomy concept but patients did not proceed to second-stage
procedure or were unresectable at the time of re-exploration
aTogether with portal vein ligation in three patients
b<2 segments
cIn one patient combined with radiofrequency ablation
dTogether with portal vein ligation during initial operation within two-
stage hepatectomy
eExtended by partial resection of segment IV
Table 4 Postoperative complications
Patients
No. %
Morbidity
Cardiopulmonary 4 6
Wound healing 5 8
Biliary leakage 7 11
Liver insufficiency
a 35
Reoperation
b 23
Mortality 1 1.5
aDefined by prothrombin time <50% and serum bilirubin >50 μmol/l on
post-op day 5 (Balzan et al. [12])
bBoth reoperations were performed due to wound healing complications
Percentage is related to whole study population
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CELIM trial [6]. In that review, critical disagreement (one
surgeon classifying a lesion as resectable and another as
non-resectable) occurred in 131 out of 1,913 decision pairs
(6.8%). This possibility of disagreement gives explanation
to the assessment of secondary resectability in those
patients of our study that experienced tumor progression
under preoperative chemotherapy.
However, to convert patients with initially unresectable
biCRC-LM into those having a resectable disease requires
the expertise of an interdisciplinary team and often the
application of multiple therapeutical regimens resulting in
individualized therapy algorithms.
Influence of two-stage hepatectomy with PVL on resection
rate and survival
R0-resection rates of straightforward LR ± preoperative 5FU-
based chemotherapy were 75% and 88%, respectively. In
contrast, following two-stage hepatectomy with PVL ±
preoperative 5FU-based chemotherapy, R0-resection rates of
63% and 60% were achieved. Although the latter are
noticeably lower, the difference was not statistically signifi-
cant (p=0.1511). The observed resection rates of two-stage
hepatectomy are comparable to those published by other
authors [17] who also did not use tumor-directed therapy
between first- and second-stage procedures. Recently,
Wicherts et al. [18] published their long-term results of
two-stage hepatectomy for initially unresectable CRC-LM
(n=59). Interestingly, the majority of patients experiencing
R0-resection (n=41) had systemic chemotherapy not only
before (95%) but also between (78%) and after (78%) the
two surgical procedures. In contrast, none of the 18 patients
failing two-stage hepatectomy had systemic chemotherapy
after the first-stage procedure. Unfortunately, the authors did
not provide detailed data on the administered chemothera-
peutic regimens. A benefit of chemotherapy between the two
surgical procedures has been also supported by Lygidakis et
al. [19] who reported a 100% secondary R0-resection rate
administering a 5FU-based regional intra-arterial chemother-
apy intensified by oxaliplatin, irinotecan, and bevacizumab.
Given that tumor progression occurs concomitantly to liver
hypertrophy [7, 20], the data of Wicherts et al. [18],
Lygidakis et al. [19] as well as our data argue for tumor-
directed therapy during liver hypertrophy which needs to be
evaluated in randomized controlled phase II clinical trials.
Our data clearly indicate that DFS as well as OS in R0-
resected patients treated by two-stage hepatectomy do not
significantly differ from those patients being with straight-
forward LR (p=0.650 and 0.435, respectively). These data
confirm recently published results of Mueller et al. [21].
Although they did not focus on biCRC-LM, they reported
5-year OS rates after R0-LR with PVO of 45.53% versus
37.67% without PVO (p=0.625). These comparable results
are remarkable taking the PVO-related induction of tumor
growth into consideration [7, 20]. Multiple factors could be
associated with this finding: the considerable inter-
individual variation in the intensity of PVO-related tumor
growth induction which in our experience does not
correlate with the extend of volume gain on an individual
basis [7], the use of preoperative systemic chemotherapy
which has been considered to independently prolong DFS
[22], and the administration of postoperative systemic
therapy in adjuvant intent. Furthermore, PVO might
function as a selection factor. Patients with highly aggres-
sive diseases likely retain unresectable due to progression
during liver hypertrophy and do not proceed to R0-LR. In
Fig. 3 Kaplan–Meier plot of cancer-specific overall survival in 47
R0-resected patients with bilobar CRC-LM. A significant survival
benefit (p=0.048) could be observed for those patients treated by
postoperative anti-cancer therapy
Fig. 2 Kaplan–Meier plot of cancer-specific overall survival in 47
patientswithcomplete(R0)resectionand17patientswithR1/2resection.
With 38 versus 19 months, the median survival for R0-resected patients
was significantly higher (p=0.035)
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detectable and accordingly secondarily resectable because
of the PVO-related growth induction, this might result in a
reduced number of residual tumor cell formations in the
remnant liver. Besides, the comparable OS rates, however,
can in part be attributed to our aggressive multimodal
approach even for metastatic recurrence after R0-LR.
Overall survival
We achieved a median OS of 38 months following R0-LR
in patients with biCRC-LM. This is significantly higher
(p=0.035) than in those patients with R1/R2-LR followed
by-palliative systemic 5FU-based chemotherapy. The latter
is comparable to first-line treatment, e.g., with 5FU,
leucovorin, and irinotecan [23]. The early dissociation of
the corresponding survival curves (Fig. 2) reflects the
advanced disease stage of patients with biCRC-LM and the
limited effectiveness of systemic chemotherapy. Hurwitz et
al. have shown in 813 patients that adding bevacizumab to
systemic 5FU-based first-line chemotherapy resulted in an
extended median survival of 20.3 months in patients with
metastatic colorectal cancer [24] However, Tol et al. [25]
recently published their results comparing capecitabine,
oxaliplatin, and bevacizumab versus the same regimen
plus cetuximab in 775 patients with previously untreated
metastatic colorectal cancer. They observed no significant
benefit in median OS by adding the second antibody
(20.3 versus 19.4 months, p=0.16), but reported mortality
rates of 1.9% (without cetuximab) and 2.7% (with
cetuximab) and incidences of any grade 3 or 4 adverse
event of 73.2% (without cetuximab) and 81.7% (with
cetuximab), respectively. Compared to these chemothera-
peutic regimens, surgical exploration offers the chance of
curation, and the corresponding morbidity as well as
mortality rates are similar or even lower (33% and 1.5%,
respectively, in our study). Therefore, attempting LR with
discontinuation of systemic 5FU-based chemotherapy is
not adversarial in patients with biCRC-LM if R0-LR seems
to be achievable.
Survival benefit of postoperative anti-cancer therapy
in adjuvant intent
T h eo b s e r v e dm e d i a nD F So f8m o n t h sa n dO So f
38 months following R0-LR in patients with biCRC-LM
are encouraging and can be attributed in part to the
administration of postoperative anti-cancer therapy in
adjuvant intent. This is highlightened by Fig. 3 indicating
that patients exposed to systemic therapy had a significantly
longer OS (p=0.048) compared to those with routine
follow-up only. Interpreting the survival curves, the effect
of systemic therapy in adjuvant intent became apparent
20 months after R0-LR and resulted in a survival benefit of
approximately 12 months in the long-term follow-up.
Although the number of patients in our study is small, this
survival benefit is encouraging and underlines the impor-
tance of a multimodal treatment in these patients. Previous
retrospective analyses have supported the benefit of such
therapy. By also including patients with unilobar disease
into their study population of 171 patients, Portier et al.
[26] observed a significantly longer DFS for those 86
patients treated by postoperative 5FU-based chemotherapy.
However, they failed to demonstrate a significant benefit on
OS. In contrast, Parks et al. [27] demonstrated in their
pooled analysis that patients subjected to postoperative
systemic 5FU-based chemotherapy experienced an im-
proved OS. Additionally, Nordlinger et al. [22] recently
published their data on perioperative FOLFOX4 chemo-
therapy in patients with resectable CRC-LM and
reported an improvement of DFS within the first 2 years
following LR for the chemotherapy group. Despite these
studies, no prospective randomized trial has evaluated
the survival benefit of intensified postoperative 5FU-
based chemotherapy. In our study, the postoperative
regimen had been heterogeneous. However, the data
argue for a survival benefit of systemic therapy in
adjuvant intent. Facing the lack of evidence in this
important question, we hardly advocate a randomized
controlled trial comparing systemic 5FU-based chemo-
therapy with specific anti-tumor therapies, e.g., anti-
CEA-radioimmunotherapy as postoperative therapy after
R0-resection of CRC-LM.
Conclusion
The significantly higher OS following R0-resection versus
R1/R2-LR justifies extended surgery within multimodal
treatment concepts in patients with biCRC-LM. The use
of two-stage hepatectomy did negatively affect neither
R0-resection rate nor DFS and OS after complete LR.
The administration of postoperative anti-cancer therapy
was associated with a significant benefit in OS. Future
controlled clinical studies should focus on innovative
targeted treatment options especially for those patients
persisting unresectable nowadays and on type and
benefit of postoperative anti-cancer therapy in adjuvant
intent.
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